Amur Minerals (GB:CRTX) has released an update.
CRISM Therapeutics Corporation has observed a notable increase in its share price, but the company reports no specific cause for this surge. Despite a previous decline since its AIM admission, the current price is thought to reflect the Board’s confidence in CRISM’s inherent value. The company is progressing towards a Clinical Trial Application for ChemoSeed and is finalizing a contract with a UK SME worth roughly £230k, anticipating a future update on this matter.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.
